Valuation : Bonesupport Holding AB

Market Cap 14.94B 1.56B 1.34B 1.26B 1.15B 2.17B 148B 2.18B 5.82B 75.21B 5.85B 5.72B 249B P/E 2026 *
47.6x
P/E 2027 * 30.1x
Enterprise Value 14.4B 1.5B 1.3B 1.22B 1.11B 2.09B 142B 2.1B 5.61B 72.48B 5.64B 5.51B 240B EV / Sales 2026 *
9.65x
EV / Sales 2027 * 7.14x
Free-Float
88.02%
Yield 2026 *
0.64%
Yield 2027 * 0.94%
1 week-0.96%
1 month-2.24%
3 months-8.01%
6 months+3.26%
Current year+12.56%
1 week 19.3
Extreme 19.3
20.96
1 month 18.69
Extreme 18.69
21.42
3 years 9.52
Extreme 9.525
35.58
5 years 3.26
Extreme 3.255
35.58
Manager TitleAgeSince
Chief Executive Officer 49 2025-08-31
Director of Finance/CFO 63 2018-10-31
Chief Operating Officer 51 2021-11-30
Director TitleAgeSince
Director/Board Member 68 2009-12-31
Chairman 70 2016-12-14
Chairman 71 2019-05-13
Change 5-day change 1-year change 3-year change Capi.($)
+3.11%-0.96%-29.74%+90.21% 1.49B
Average -29.74%+90.21%
Weighted average by Cap. -29.74%+90.21%

Financials

2026 *2027 *
Net sales 1.49B 156M 134M 126M 115M 216M 14.76B 217M 581M 7.51B 584M 571M 24.89B 1.97B 206M 177M 167M 152M 286M 19.52B 287M 768M 9.93B 772M 755M 32.92B
Net income 318M 33.19M 28.63M 26.93M 24.54M 46.14M 3.15B 46.39M 124M 1.6B 125M 122M 5.31B 503M 52.44M 45.23M 42.55M 38.76M 72.89M 4.98B 73.28M 196M 2.53B 197M 193M 8.39B
Net Debt -543M -56.59M -48.82M -45.92M -41.83M -78.67M -5.37B -79.09M -211M -2.73B -212M -208M -9.06B -855M -89.17M -76.92M -72.35M -65.91M -124M -8.46B -125M -333M -4.3B -335M -328M -14.27B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
-
Date Price Change
26-09-01 20.24 +3.11%
26-08-31 €19.63 -4.24%
26-08-28 €20.50 0.00%
26-08-27 €20.50 +0.10%
26-08-26 €20.48 +0.69%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
218.60SEK
Average target price
356.58SEK
Spread / Average Target
+63.12%

Quarterly revenue - Rate of surprise